Editas Medicine (EDIT) and NewLink Genetics (NASDAQ:NLNK) Head-To-Head Analysis – The Lincolnian Online
|
Editas Medicine (EDIT) and NewLink Genetics (NASDAQ:NLNK) Head-To-Head Analysis
The Lincolnian Online It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 … |
